A comparative study on the inhibitory effects of commonly used clinical drugs on in vitro fibroblasts from recurrent pterygium

• DOI: 10.3760/cma.j.issn.2095-0160.2017.06.006
• Publication Date: 2017-06-10
• Authors: Yajie Sun; Tingting Lin; Yanjin He; Limin Zhu; Yang Gao
• Keywords: Mitomycin C; Pterygium; Immunochemistry; IC50

Background Pterygium is one of the common ocular surface disorders, and main drugs for pterygium include dexamethasone (DXM), interferon α-2b (IFN-α2b), mitomycin C (MMC), 5-fluorouracil (5-FU), cyclosporin A (CsA) tacrolimus (FK506). However, efficacy these on fibroblasts from recurrence unelucidated.

Objective This study was to compare DXM, IFN-α2b, MMC, 5-FU, CsA FK506 proliferation apoptosis recurrent pterygium-derived in vitro.

Methods The specimens were collected during surgery Tianjin Medical University Ophthalmological Hospital May 2015 July 2016 under written informed consent.Fibroblasts isolated cultured by explant culture method identified immunochemistry.DXM, added into medium 48 hours, respectively, cells without drug used as control group.The inhibitory efficiency different concentrations cell assayed counting kit-8 (CCK-8), 50% inhibiting concentration (IC50) calculated.The treated IC50 dose apoptotic proportion cycle assessed flow cytometry analysis.The expression proliferating nuclear antigen (PCNA) after detected immunochemistry.

Results Cultured grew well with fusiform shape radial arrangement.Vimentine showed positive keratin absently expressed cells.The (3.5×103±2.83×10-2)mg/L, (6.1×102±3.6×10-3)mg/L, (3.2×10-1±1×10-4)mg/L, (2.2×101±1.2×10-3)mg/L, (6.3×101±2.5×10-3)mg/L (6.0×101± 0.0×100) mg/L FK506, respectively.In hours drugs, ratio (35.00±3.21)%, (30.37±1.67)%, (26.11±0.75)%, (22.01±0.07)%, (20.95±1.68)% (19.85±0.52)% IFN-α2b group, MMC DXM group 5-FU which significantly higher than (11.38±2.18) % (all at P<0.05). The G0/G1 phase, S phase G2/M (85.64±2.62)%, (5.29±1.56)% (2.73±2.66)% reduced, while that or considerably increased various groups P<0.05), blocking turn CsA, FK506.The expressional rate PCNA (95.00±2.00)%, (82.67±5.04)%, (80.00±2.78)%, (64.00±6.55)%, (38.00±3.00)%, (32.00±4.36)% (29.67±3.02)% showing a significant difference among (F=25.995, P<0.01), lower P<0.05).

Conclusions DXM, are all able inhibit promote vitro, appear have stronger effect.

Key words: Pterygium/surgery; Pterygium/drug therapy; Recurrence; Fibroblasts; Dexamethasone; Interferon-α; Mitomycin C; 5-Fluorouracil; Cyclosporin A; Tacrolimus; Cells,